Roche Media News http://www.roche.com/ en-gb Inhouse The latest media news from Roche Actemra inhibits joint damage and improves physical function of patients with Rheumatoid Arthritis http://www.roche.com/med-cor-2008-05-09 Fri, 09 May 2008 06:00:00 GMT Roche announced today that Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients` physical function after one year of therapy, leading to a better quality of life. Roche continues solid sales growth in first quarter of 2008 - both divisions significantly outpace their markets http://www.roche.com/med-cor-2008-04-17 Thu, 17 Apr 2008 05:00:00 GMT Double-digit growth of key products more than outweighs one-time impact of major Tamiflu pandemic orders in year-earlier period Actemra approved in Japan to treat patients with rheumatoid arthritis http://www.roche.com/med-cor-2008-04-16b Wed, 16 Apr 2008 06:00:00 GMT Roche announced today that their alliance partner company Chugai has received approval in Japan for the use of its innovative treatment, Actemra (tocilizumab), in patients suffering from rheumatoid arthritis (RA). Roche fully acquires privately-owned biotech company Piramed http://www.roche.com/med-cor-2008-04-15 Tue, 15 Apr 2008 05:30:00 GMT Roche announced today that it will acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI3-kinase (PI3-K). The PI3-K pathway is known to play an important role in disease progression and in resistance to chemotherapeutics in cancer cells. Pre-clinical studies have demonstrated the activity of PI3-K inhibitors in a broad range of tumours such as breast and lung cancer, as well as their potential importance in treating inflammatory diseases such as rheumatoid arthritis. Roche raises dividend by 35 percent http://www.roche.com/med-cor-2008-03-04 Tue, 04 Mar 2008 11:50:00 GMT Annual General Meeting approves Annual Report and financial statements for 2007 Herceptin approved in Japan for early treatment in patients with HER2-positive breast cancer http://www.roche.com/med-cor-2008-02-29 Fri, 29 Feb 2008 06:30:00 GMT Roche announced today that its majority-owned subsidiary Chugai Pharmaceutical Co. Ltd received approval from the Japanese Health Authority for the use of Herceptin in the early treatment for women with HER2-positive breast cancer. The approval was based on the impressive HERA (HERceptin Adjuvant) study results demonstrating that Herceptin significantly reduced the risk of death and recurrence by more than one third(34% and 36% respectively), in women with HER2-positive early-stage breast cancer when given following surgery and standard chemotherapy.